diarrhea in Extend­ed release study [Outliers]

posted by Researcher101 – Egypt, 2020-09-23 23:53 (1744 d 06:32 ago) – Posting: # 21935
Views: 3,474

Dear All, I'm asking if I have a study on product containing two actives (one IR and the other extended release) and a participant had a diarrhea after Tmax of the IR active and through the Tmax of the XR active. should I exclude the participant from the study? or include him in the XR active statistical calculation and exclude in the IR? :confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,426 posts in 4,929 threads, 1,679 registered users;
63 visitors (0 registered, 63 guests [including 10 identified bots]).
Forum time: 06:26 CEST (Europe/Vienna)

Half the harm that is done in this world
Is due to people who want to feel important.    T. S. Eliot

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5